Roxadustat is in clinical development for the treatment of anemia of chronic inflammatory disease. Treatment of anaemia due to chronic disorders. Roxadustat was developed by Fibrogen Inc..
The API has now reached off-patent status, after being launched in 2018.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Roxadustat was exported from India in 2023 , with an average price over the period of $8010 /kg.
The key suppliers were Mylan (Viatris), with a focus on markets in Asia Pacific.

For enquiries regarding more detailed trade data of Roxadustat and many others, contact info@pharmacheminvestor.com